Neuro News Roundup: Multiple Sclerosis

New recommendations aim to reduce the risk for progressive multifocal leukoencephalopathy (PML) with use of natalizumab in patients with relapsing remitting multiple sclerosis (RRMS). RRMS patients taking natalizumab who seroconvert to high levels of signaling antibodies are at increased risk of PML. In a new finding, seven loci have been added to the list of genuine MS genetic risk factors.